Parker, Seth J. http://orcid.org/0000-0001-7971-8848
Encarnación-Rosado, Joel
Hollinshead, Kate E. R.
Hollinshead, David M.
Ash, Leonard J.
Rossi, Juan A. K.
Lin, Elaine Y.
Sohn, Albert S. W.
Philips, Mark R. http://orcid.org/0000-0002-1179-8156
Jones, Drew R.
Kimmelman, Alec C.
Funding for this research was provided by:
American Cancer Society (132942-PF-18-215-01-TBG, RSG-13-298-01-TBG)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01CA188048, P01CA117969, R35CA232124, R01GM095567, P30CA016087)
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
Article History
Received: 9 October 2020
Accepted: 27 July 2021
First Online: 12 August 2021
Competing interests
: A.C.K. has financial interests in Vescor Therapeutics, LLC. A.C.K. is an inventor on patents pertaining to KRAS-regulated metabolic pathways, redox control pathways in pancreatic cancer, targeting GOT1 as a therapeutic approach, and the autophagy control of iron metabolism. A.C.K. is on the SAB of Rafael/Cornerstone Pharmaceuticals. A.C.K. is a consultant for Deciphera and Abbvie. The other authors declare no competing interests.